WES analysis of 60 pRCC specimens revealed six tumours (10%) with mutations in the four key genes, NFE2L2, KEAP1, CUL3 and BACH1, of the NRF2‐ARE pathway. This evidence concerns the gene NFE2L2 and neoplasm.